Try our Advanced Search for more refined results
Health - April, 2010
198 articles
- FDA Dropped Ball On Heparin Probe: GOP Lawmakers
- Watson Faces Suits Over Trilipix, Rapamune ANDAs
- Anthem Withdraws Rate Hike After Errors Found
- Wyeth, Schwarz Escape Reglan Failure-To-Warn Suit
- Law Firms Prepare For Wave Of Health Care Work
- Axiom Off Hook For Infringement Of Electrotherapy IP
- Hospital Can Sue Rival On Antitrust Grounds: 11th Circ.
- Neurontin Purchasers Ask To Amend Class Definition
- J&J Unit Settles Off-Label Marketing Claims For $81M
- 2nd Circ. Urges En Banc 'Pay-For-Delay' Rehearing
- Lasik Patients Oppose TLC Vision Ch. 11 Plan
- Grassley Pushes For Post-Market Drug Safety Measures
- Schwarz Pays $22M To Settle Medicare Fraud Cases
- CellCyte CEO Fraud Claims Can Move Forward
- Grassley Pushes States To Beef Up False Claims Acts
- Dentsply Strikes Deal To Avoid Antitrust Trial
- Medtronic To Buy ATS Medical In $370M Deal
- Allstate Challenges Wyeth Win In Ativan Coverage Suit
- King & Spalding Lures Sidley Health Industry Pro
- Sandoz Resolves Takeda Patent Dispute Over Actos
- Fed. Circ. Upholds Invalidity Of J&J Concerta Patent
- More Plaintiffs Tossed From ReNu Lens Solution MDL
- WellPoint Ends Rescission, Delays Rate Hikes
- 5 Things Patent Examiners Wish You Would Do
- Forest, Orchid Resolve Namenda Patent Fight
- Boston Scientific Stent Fraud Class Action Tossed
- Abbott, Lilly, Others Hid Miscarriage Drug's Risks: Suit
- A Path To Accountable Care Runs Through The FTC
- CIBA Loses Injunction Bid In Acuvue Case
- Vioxx Ruling A Boost For Securities Suits: Attys
- Alcon Settles Synergetics Tying Suit For $32M
- 280K Defibrillators At Risk For Malfunction, FDA Warns
- Biotest Contract Suit Over Nabi-HB Remains In Fla.
- Guidant's $296M Plea Deal In Defibrillator Case Rejected
- Fed. Circ. Nixes $4.4M In Sanctions Against McDermott
- FTC Adds More Defendants To Government Grant Case
- Avigen, MediciNova Settle Shareholder Suit Over Deal
- The EU Probe Into Pharmaceutical Patent Settlements
- Teva Attacks Watson Over Generic Menopause Drug
- Novartis Manager Withheld Info About Employee's Rape
- AstraZeneca Set To Seal $520M Deal In Seroquel Case
- FDA Unveils New Analysis Rules For Medical Devices
- Shire Targets Teva Over Generic Intuniv
- Drugstores Ask Court To Reconsider Plavix Ruling
- Fed. Circ. To Review Inequitable Conduct Standards
- Davis Polk Reps Charles River In $1.6B WuXi Deal
- Suit Accusing Amgen Of Kickbacks Gets The Boot
- Clients Say Fen-Phen Lawyer Overcharged $29M
- Abbott, Hospira Off Hook In ERISA Class Action
- Latham Advises Thoratec In $136M Danaher Deal
- Aetna, Humana Latest To Settle In OxyContin MDL
- Celgene, Novartis Settle With Barr Over Generic Ritalin
- Jury Finds Pfizer's Protonix Patent Valid
- WebMD Affiliates Fail In Appeal Over Fraud Coverage
- Class Cert. Stripped In Fla. Doctor Bonuses Suit
- Pay-For-Delay Deals Remain In FTC's Crosshairs
- UBS, E&Y To Pay $250M In HealthSouth Fraud Case
- FDA Takes Action To Reduce Infusion Pump Risks
- HHS To WellPoint: Don't Drop Breast Cancer Patients
- 'Most Favored Nation' Clauses And Health Insurers
- Group Asks SEC To Review CVS Stock Sales
- WellPoint Unit Denied Profits On Health Plan Rates
- Medtronic Recall Earns FDA's Most Serious Rating
- Focalin IP Deal Between Celgene, Actavis Wins OK
- Wal-Mart Medical Treatment Action Stayed For Appeal
- Northern Ill. Patent Rules Have Yet To Boost Filings
- Watson Appeals Loss In Seasonique Spat With Teva
- $4.5M MediCor D&O Settlement Approved
- Trademark Owners Must Watch Out Post-MedImmune
- Pfizer Responds To FDA Over Geodon Clinical Trial
- Philips Fails To Keep Antitrust Claims In Oximeter Suit
- St. Jude Settles Doctor's Pacemaker Patent Action
- Bayer Drops Case Against Lupin Over Generic Cipro
- Senator Wants To Snuff Out Candylike Tobacco
- Congressional Testimony: What To Do (And Not Do)
- Boehringer Pays $7.75M To Settle AWP Allegations
- New Damages Trial Granted In Wal-Mart Medicine Suit
- Salt Report Spurs FDA To Form Attack Plan
- Obama Taps Harvard Prof. To Run Medicare, Medicaid
- Ex-Tenet GC Defeats Medicare False Claims Suit
- 3 Claims Of Schering's Zetia Patent Found Invalid
- Synthon Seeks To Shift Lilly Adcirca Battle To NC
- Steris Offers Device Rebates To Settle FDA Claims
- BarrierMed CEO Settles SEC $11M Fraud Suit
- Howmedica Faulty Hip Implant Suit Preempted: Judge
- No Cert For Fresenius In Baxter Dialysis Patent Case
- Eli Lilly To Buy Back Cymbalta Rights For $400M
- Pfizer, Wyeth Antitrust Complaint Nixed For 3rd Time
- Mars Sues Supplement Makers Over Cocoa Patents
- Miss. High Court Revives State AWP Suit Against Bayer
- Biovail Files 2nd Suit Over Watson's Aplenzin ANDA
- Reverse Payments, Mergers Take Center Stage In Q1
- High Court Remands Class Action, Citing Shady Grove
- MDL Panel Won't Centralize Pain Pump Suits
- 3rd Circ. Upholds Dentsply Wins In Antitrust Cases
- Secondary Payor Liability In Settling Medicare Claims
- Drugstores Denied Injunction In Calif. Medicaid Suit
- Novartis, Astellas, GSK Ads Misbranded Drugs: FDA
- Lundbeck Notches Win In Danish Cipralex Case
- Biovail Hits Paddock With 2nd Suit Over Aplenzin ANDA
- Davis Polk Reps Oracle In $685M Phase Forward Deal
- Mayo Foundation, Philips Clear Up Imaging Patent Spat
- No Stay For Apotex Amid Sanofi's Plavix Damages Push
- MedQuist, CBay Get Bankrupt Spheris For $116M
- Insurer Wants Quick Appeal In $7M MedAssets Suit
- Fed. Circ. Rules Use Code Off Limits In Prandin IP Case
- Insurers Will Try To Dodge Spending Reforms: Report
- NYC's St. Vincent's Files Ch. 11 Amid Closures
- Ranbaxy's US Branch Recalls Antibiotics Over Color
- Viagra Study Documents Can't Be Released: Judge
- Santarus' Patents For Heartburn Drug Invalid: Judge
- GSK Asks Again For Dismissal Of Wellbutrin IP Claims
- AstraZeneca Loses Bid To Nix Toprol Antitrust Suits
- Ill. Patients Appeal Denied Antitrust Class Cert. Bid
- Exclusive Gene Patents Can Hurt Competition: Study
- Sens. Grill Holder On Securities, Health, Antitrust
- Pozen, Teva Bury Hatchet Over Treximet
- Stryker Surgical Implant Kickback Suit Loses Legs
- Counsel Accused Of Improper Conduct In Fraud Case
- Case Over GE's Omniscan Survives Dismissal Bid
- Home Care Workers Sue NYC Agency For OT Wages
- The Economic Impact Of New MMSEA Regulations
- Ga. Joins States' Health Care Suit Over AG's Refusal
- Blue Cross Mich. Agrees To Cover Autism Therapy
- Bayer Updates Blood Clot Risk Info For Yasmin Label
- Endo, Penwest Reach Opana License Deal With Barr
- FDA Proposes Rules For Listing Side Effects In Ads
- Perrigo, Graceway Strike Deal Over Generic Aldara
- K-Dur Direct Purchasers Appeal Antitrust Suit Ruling
- A Viable Theory Of Sham Infringement Litigation?
- Boston Sci Misled Investors After Guidant Deal: Suit
- $110M E-Ferol Settlement Gets Final Approval
- Recapture Rule Dooms 4 Claims Of MBO Syringe Patent
- GSK, Glenmark Resolve Malaria Drug Patent Dustup
- Boston Sci Appeals Cordis Stent Patent Win
- Nationwide To Settle With Fixed-Pay Insurance Class
- Health Care Reform And 'Grandfathered Plans'
- Perrigo Triumphs In Trial Over Rexall's False Ad Claims
- Congress To Study Smokeless Tobacco Use In MLB
- Applied Medical Fights $4.8M Verdict In Surgery IP Suit
- Cohen Milstein OK'd As Counsel In Plasma Pricing MDL
- Warner Chilcott, Roche Sue Mylan Over Actonel ANDA
- Another Weapon In The Midsize Firm Arsenal
- Novartis Ignored Consultant's Sex Bias Findings: Atty
- Radiation Therapy Devices Face FDA Scrutiny
- Medtech, DenTek Resolve Mouth Guard Patent Battle
- Smith & Nephew Seeks New Trial In Kinetic IP Suit
- FDA Warns Edwards Over Heart Device Reporting
- Fed. Circ. Upholds Icos' Ownership Of Cialis Patents
- Bioenvision Shareholder Suit Rightly Nixed: 2nd Circ.
- US Oftalmi Recalls Eye, Nose Drops Over Sterility
- Genesis, Shippert End Feud Over Liposuction Patent
- Hemispherx's Hostile Takeover Suit Stays Alive
- FDA Cracks Down On Spas' Lipodissolve Claims
- PharMerica's Contract Interference Suit Survives
- IT Worker Hits Wash. Blue Cross With OT Suit
- Whistleblower Protections Under Health Care Bill
- 3rd Circ. Affirms Slimmer Case Against Ex-BMS Exec
- FDA Warns Gilead, Biogen Over Drug Ads
- J&J, Omnicare Hit With Class Action Over Kickbacks
- 5 More States Join Suit Against Health Care Law
- Novartis Sex Bias Class Action Goes To Trial In NY
- Aware Settles Acacia Unit's Medical Imaging IP Suit
- ITC OKs ENI-Cargill Glucosamine IP Deal In 337 Case
- Health Care Reform Means New Disclosure Rules
- Last Defendants Settle With Sanofi Over Eloxatin
- Bristol-Myers, Takeda Hit With False Marking Suits
- AstraZeneca Win In Seroquel Bellwether Affirmed
- Ace Seeks Zurich Funds For $4M Payout To Worker
- UGA To Pay Inventor $20M Over Restasis Patents
- Purdue Settles Ark. Fund's OxyContin Antitrust Suit
- Guidant Pleads Guilty In Defibrillator Safety Case
- Apotex Asks DC Circ. To Stay Teva's Hyzaar Exclusivity
- Sperm Bank Not Liable For 'Defective' Semen: 3rd Circ.
- Merck Sues Novartis Unit Over Cancidas ANDA
- NeoPharm Investors' Class Action Trimmed
- Ballard Spahr Leads Medegen In $225M CareFusion Deal
- Medtronic To Appeal Edwards' $74M Heart Valve IP Win
- Mayer Brown Off Hook For $17M Malpractice Claim
- Dentsply Must Face Rivals' Federal Antitrust Claims
- Fed. Circ. Bolsters Hearing Components' Audio IP Win
- Pa. Supreme Court Blocks Appeal In Prempro Case
- Venable Shot Down As Counsel For Unsecured Creditors
- Fed. Circ. Further Untangles HIF Bio Inventorship Fight
- Teva's Gemzar ANDAs Infringe Lilly Patent: Judge
- Fed. Circ. Nixes Suit To Invalidate Kinetic Patents
- USPTO Revises Appeal Briefs Procedure
- La. Allowed To Pursue Vioxx Refund From Merck
- Lilly, Sandoz Can't End Generic Prozac Suicide Case
- Sanofi Settles With Teva, Others Over Generic Eloxatin
- FDA Rolls Out Pediatric Info Rule For Device Makers
- Teva Gets Win In Birth Control IP Battle Against Watson
- Hospital, Health Plans End Oxycontin Antitrust Suits
- La. Health Insurance Law Unconstitutional: 5th Circ.
- Novo Nordisk Patent Suit Over Prandin Nixed
- Teva Fights To Keep Exclusivity On Hypertension Drugs
- Lilly Settles La. AG Zyprexa Claims For $20M
- Alternative Fee And Billing Arrangements: A Primer